CERo Therapeutics Earnings Per Share vs. EBITDA
| CERO Stock | 0.06 0.01 19.00% |
For CERo Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CERo Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CERo Therapeutics Holdings, utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CERo Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CERo Therapeutics Holdings, over time as well as its relative position and ranking within its peers.
CERo |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CERo Therapeutics EBITDA vs. Earnings Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining CERo Therapeutics's current stock value. Our valuation model uses many indicators to compare CERo Therapeutics value to that of its competitors to determine the firm's financial worth. CERo Therapeutics Holdings, is number one stock in earnings per share category among its peers. It also is number one stock in ebitda category among its peers . CERo Therapeutics reported last year EBITDA of (2.44 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CERo Therapeutics' earnings, one of the primary drivers of an investment's value.CERo EBITDA vs. Earnings Per Share
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
CERo Therapeutics |
| = | (1.19) X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
CERo Therapeutics |
| = | (2.44 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CERo EBITDA Comparison
CERo Therapeutics is currently under evaluation in ebitda category among its peers.
CERo Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in CERo Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CERo Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of CERo Therapeutics' change in net profit over the period of time. It can combine multiple indicators of CERo Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 127.9 K | 121.5 K | |
| Interest Income | 127.9 K | 121.5 K | |
| Operating Income | -2.9 M | -3.1 M | |
| Net Loss | -10.6 M | -11.2 M | |
| Income Before Tax | -2.4 M | -2.3 M | |
| Total Other Income Expense Net | 491.6 K | 467 K | |
| Net Loss | -2.5 K | -2.7 K | |
| Income Tax Expense | 94.8 K | 90.1 K | |
| Income Quality | 0.60 | 0.57 |
CERo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on CERo Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CERo Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CERo Therapeutics' important profitability drivers and their relationship over time.
Use CERo Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CERo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CERo Therapeutics will appreciate offsetting losses from the drop in the long position's value.CERo Therapeutics Pair Trading
CERo Therapeutics Holdings, Pair Trading Analysis
The ability to find closely correlated positions to CERo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CERo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CERo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CERo Therapeutics Holdings, to buy it.
The correlation of CERo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CERo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CERo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CERo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your CERo Therapeutics position
In addition to having CERo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
To fully project CERo Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of CERo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include CERo Therapeutics' income statement, its balance sheet, and the statement of cash flows.